Search for a rare disease
Other search option(s)
Autosomal dominant intellectual disability-craniofacial anomalies-cardiac defects syndrome
Disease definition
A rare genetic neurodevelopmental disorder characterized by global developmental delay (DD) and variable degrees of intellectual disability (ID) with delayed or limited/absent speech development associated with neonatal hypotonia, feeding difficulties, cardiac anomalies and dysmorphic facial features, predominantly broad nasal tip and thin, tented upper lip. Microcephaly, frequent infections, gastrointestinal and/or ocular anomalies have also been described.
ORPHA:457193
Classification level: Disorder- Synonym(s):
- Arboleda-Tham syndrome
- KAT6A syndrome
- Prevalence: <1 / 1 000 000
- Inheritance: Autosomal dominant
- Age of onset: Neonatal, Infancy
- ICD-10: Q87.8
- OMIM: 616268
- UMLS: -
- MeSH: -
- GARD: -
- MedDRA: -
Summary
Epidemiology
About 76 patients are reported in the scientific and medical literature; however, more than 300 are known to patient organizations.
Clinical description
Most patients present with neonatal hypotonia and feeding difficulties, often requiring nasogastric intubation. The developmental delay and intellectual disability are of variable severity. All patients reported presented with language delay/deficits (mostly expressive limitations) and some patients are non-verbal into adulthood. About half of the patients are diagnosed with a cardiac abnormality (atrial septal defects, ventricular septal defect, patent foramen ovale and/or persistent ductus arteriosus). Other frequent problems are gastroesophageal reflux, constipation and eye abnormalities (strabismus, amblyopia and less frequently refractory errors). A facial gestalt might be recognized with a broad nasal tip, thin tented upper lip and bi-temporal narrowing. Microcephaly occurs in a minority of the patients. Other less common features are autism spectrum disorders, sleep disturbances, craniosynostosis, seizures, increased susceptibility to infections, haematological and immunological abnormalities and bowel obstruction.
Etiology
The disorder is caused by heterozygous pathogenic variants affecting the KAT6A gene (8p11.21) which encodes for a lysine (K) acetyltransferase 6A that forms part of a histone acetyltransferase complex regulating transcriptional activity and gene expression. Genotype-phenotype correlations suggest that variants affecting the last two exons of the gene (16 and 17) are associated with a more severe phenotype.
Diagnostic methods
The diagnosis is established by whole exome or genome sequencing or multi-gene panel including the KAT6A gene. Cases due to copy number variants might be identified by array-comparative genomic hybridization.
Differential diagnosis
The syndrome has an extensive differential diagnosis in the context of syndromic DD/ID.
Antenatal diagnosis
Prenatal diagnosis is possible where the pathogenic variant has previously been identified in a family member.
Genetic counseling
The disorder is autosomal dominant. Most cases are sporadic due to de novo variants, but familial and germinal mosaicism cases have been reported. For the affected individual, the risk of transmission is 50% for each pregnancy.
Management and treatment
Management is symptom-based and requires a multidisciplinary approach. Early speech and language therapy can improve oro-motor dyspraxia and articulation deficits. Augmentative and alternative communication tools are important aids. All patients require early cardiac evaluation with electrocardiogram and echocardiogram. Tube feeding might be required in infants, and all patients should be monitored for signs and symptoms of gastroesophageal reflux. Older patients might need long term medication with laxatives. Bowel obstruction should be considered in case of abdominal pain, and increased vomiting/reflux. Follow-up should include evaluation of behavioural/social difficulties, complete blood count and immune profile for recurrent infections, and regular assessment of vision. For sleep disorder, study of obstructive apnoea is recommended and melatonin supplementation might be considered.
Prognosis
Long term prognosis of the disorder is unknown.
A summary on this disease is available in Español (2021) Français (2021) Nederlands (2021)
Detailed information
General public
- Article for general public
- English (2017, pdf) - Unique
- Russian (2020, pdf) - Unique


Additional information